 PITTSBURGH, Aug. 04, 2021 GLOBE NEWSWIRE -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. NASDAQ: AVCO aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks. Cancer immunotherapy, which stimulates and trains a patients own immune system to target and kill tumors while leaving healthy cells intact, is an effective treatment for many cancer patients. 